|
|
|
|
|
| April 29,
2010 | ISSUE NUMBER 146 VOL 8 |
Sales
Biotech Industry Profits Grow $3.7B
After a year of losses, the biologics sector got a big boost in profits in 2009. However, with companies holding back on R&D spending and venture capitalists becoming more frugal, can the industry possibly see further growth?
Disclosure
Sunshine Laws Stump Compliance Departments
A new Cegedim-Dendrite study shows just how ill-equipped pharmaceutical companies are to deal with spending disclosure legislation, and how many are turning to third parties to do the job.
Awards
Patient Adherence Awards Winners Revealed
Lilly’s first quarter numbers dipped from last year, citing, among other factors, The annual CBI Adherence Awards are in the can, and some major players came out on top this year. And the winners are…
Healthcare Reform
Huckabee and Johnston Expound on Reform
SAS invited some pretty heavy players to keynote its Health Care & Life Sciences Executive Conference. While differences in opinion were obvious, the conclusion remained the same: Change is upon us.
New & Noteworthy
Woman of the Year: Deirdre Connelly
As president of GSK's North American Pharmaceuticals, Deirdre Connelly has the daunting challenge of trying to turn around the sluggish US market. If she succeeds, Connelly may find herself auditioning to be the first female Big Pharma CEO.
|
| 
|
 // Aragon Pharmaceuticals added Brett Zbar to its board of directors.
// Gelesis appointed John LaMattina to its board.
// Declath Systems hired Peter Graham as EVP and general counsel.
// Orexigen Therapeutics appointed Wendy Dixon to its board.
// InteKrin Therapeutics hired Roman Skowronski as VP of clinical development.
// Gelesis added former Pfizer global R&D president John LaMattina to its board.
// Satori Pharmaceuticals elected Steven Holtzman, co-founder, chairman of the board. It also appointed Jeff Jonker chief business officer.
// Marshall Edwards named Daniel Gold its new CEO.
// Amgen promoted Robert Bradway president and COO. He had been EVP and CFO.
// Renhuang Pharmaceuticals appointed Dianjun Pi to its board.
// |
|
May 24–27 Contract Lifecycle Management– I-many Summit 2010 User Conference
Miami, FL
June 13–17, 2010 Drug Industry Association’s Annual Meeting
Washington DC
Jun 22–23 Disease Education and Bio/Pharmaceutical Product Promotion Using Social Media Tools
Alexandria, VA
Jun 28–29 Clinical R&D Compliance Forum
Philadelphia, PA
Jul 26–27 Bio/Pharmaceutical Summit: Optimize Market Research and to Drive Accurate Product Forecasts
Philadelphia, PA
Jul 29–30 5th Annual Congress on Clinical Supply Chain Management
Princeton, NJ
Sep 9–10 Clinical Trials in Latin America
Lima, Peru
Sep 29–30 6th Annual Bio/Pharmaceutical and Medical Device Product Recalls Summit
Washington, DC
|
|
|
|
 |
|
 |
|
 |
| If you plan to enter emerging markets over the next 3 years, what will be your primary entry strategy? |
|
|
|
|
You
are subscribed to %%list.name%% as %%emailaddr%%. Click here to unsubscribe or edit your member profile.
To
ensure delivery to your Inbox, please add us to your
address book. If you need help doing this, click
here.
Advanstar Communications provides certain customer contact data (such as customers' names, addresses, phone numbers and e-mail addresses) to third parties who wish to promote relevant products, services and other opportunities which may be of interest to you. If you do not want Advanstar Communications to make your contact information available to third parties for marketing purposes, simply call (toll free) 1-866-529-2922 at any time, or fax us at 1-218-740-6417. Outside the U.S., please phone 1-218-740-6395. Contact us by mail at Advanstar Communications Inc., 131 West First St., Duluth, MN 55802-2065, USA.
|
|
